Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Skinvisible Q3 2026 Results: Net Loss of $256K, Loss Widens

Skinvisible, Inc. reported a net loss of $778,401 for the nine months ended September 30, 2026, with a significant accumulated deficit of $41.8 million raising substantial doubt about its ability to continue as a going concern. The company remains in a pre-revenue or early-revenue stage, generating only $16,166 in revenue during the first nine months of 2026 while relying on related-party loans to fund operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Gross profit0.00.0
Net income-0.3-0.3

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+23.3%
Gross margin100.0%
Source

10-Q filed with the SEC, OTC: SKVI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Skinvisible, Inc.: key numbers

Share price
$0.1800Close, Nov 13
Market cap
$973K
Shares outstanding
5.4MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.